Gsk (GSK) Common Equity (2009 - 2026)

Gsk (GSK) has 18 years of Common Equity data on file, last reported at $23.0 billion in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 20.35% year-over-year to $23.0 billion; the trailing twelve-month figure through Jun 2026 stood at $23.0 billion (up 20.35% YoY), and the FY2025 full-year result was $21.2 billion, up 26.88% from the prior year.
• Common Equity was $23.0 billion for Q2 2026 at Gsk, down from $23.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $36.0 billion in Q1 2022 to a low of $10.3 billion in Q3 2022.
• A 5-year average of $19.0 billion and a median of $17.3 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 65.74% in 2022 and jumped 55.61% in 2023, its largest moves.
• Gsk's Common Equity stood at $11.8 billion in 2022, then soared by 34.1% to $15.9 billion in 2023, then rose by 5.76% to $16.8 billion in 2024, then advanced by 26.36% to $21.2 billion in 2025, then advanced by 8.58% to $23.0 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $23.0 billion in Q2 2026, $23.5 billion in Q1 2026, and $21.2 billion in Q4 2025.